Cellceutix Corp. (CTIX.OB) Moves Closer to Human Trials with Kevetrin™
Cellceutix Corp. announced today that they have reached agreements with PharPoint Reasearch and Medical Research Consulting Services for Phase 1 clinical trials of their lead compound, Kevetrin, which is being developed to target drug-resistant cancers. PharPoint will handle data management and statistical analysis while Medical Research will be responsible for clinical monitoring throughout the human trials. Art Holmes, President of PharPoint, was quoted in the press release as stating, “We are pleased to have the opportunity to work with Cellceutix and to bring our skills to bear on the Kevetrin Phase 1 study,” Mr. Holmes continued, “From a corporate standpoint,…